Vol. 21/No. 14 | OncologyLive

UGN-102 Emerges As Potential Surgical Alternative for Low-Grade, Intermediate-Risk NMIBC

July 18, 2020


Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

Ramucirumab Combination Expands Lung Cancer Options

July 16, 2020


Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations.

Patient Outcomes Support Cabazitaxel Over Standard in mCRPC

July 14, 2020


Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.